This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More
Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer. … Read More
Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies. This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies. The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody,… Read More
GSK has announced a strategic collaboration with biotechnology company LTZ to advance novel myeloid cell engagers (MCEs) in oncology. The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development… Read More
DDW Editor Reece Armstrong speaks to Aron Knickerbocker, CEO of Aulos Bioscience, about the company’s efforts in the immuno-oncology field and how it is hoping to revitalise a therapeutic area that initially held promise many years ago. The number of available treatment options for cancer patients has risen drastically… Read More
Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease – with improved… Read More
GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More
Jamie Gould, Consultant at The RSA Group, explores the talent landscape of the immuno-oncology sector. Immuno-oncology harnesses the power of the body’s immune system to fight cancer. This exciting field is rapidly evolving and already delivering a revolution in cancer therapeutics with a steady stream of recent approvals. In June… Read More
Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Read More
The US Food and Drug Administration (FDA) has approved Vyloy (zolbetuximab-clzb) for locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults… Read More
Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. This eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More
Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More
